Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexlansoprazole for healing and maintenance of erosive esophagitis in children 2–11 years
2022-501350-11-00Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of dexlansoprazole in erosive esophagitis (EE) and gastroesophageal reflux disease (GERD), sponsored by Takeda. Primary endpoints: Healing of erosive esophagitis by Week 8 and Maintenance of healed erosive esophagitis over 16 weeks. Started Feb 2023; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2022-501350-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501350-11-00.